SequelSEC

Hepion Pharmaceuticals, Inc. HEPA

Pharmaceutical Preparations · CIK 0001583771 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2023-12-31
Operating income
-$48.45M
Fiscal year ended 2023-12-31
Free cash flow
-$40.90M
Fiscal year ended 2023-12-31

Hepion Pharmaceuticals, Inc. (HEPA) reported revenue of $0 and net income of -$48.93M for the fiscal year ended 2023-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Hepion Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Hepion Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-31
Revenue$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$48.45M-$45.49M-$30.40M-$20.15M
Net income-$48.93M-$42.20M-$32.72M-$20.35M
Research & development$35.64M$33.27M$20.40M$12.00M
Weighted-average diluted sharesUnavailableshares 3.81Mshares 70.29Mshares 9.68M
Pretax income-$49.34M-$45.08M-$32.72M-$20.32M
Income tax expense-$409.02K-$2.88M$0$30.58K
Diluted EPS$-616.07$-11.90$-0.47$-2.10
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$9.62M$10.35M$10.01M$8.15M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Hepion Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailable
Total assets$18.09M$60.24M$103.55M$48.65M
Current assets$17.49M$56.50M$97.45M$42.63M
Total liabilities$10.81M$10.39M$10.56M$8.12M
Current liabilities$5.29M$7.89M$8.21M$4.66M
Total equity incl. NCI$7.28M$49.86M$93.00M$40.52M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailable$0$1.87M$1.87M
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.35M$2.67M$2.45M$3.72M

Cash flow

Hepion Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$40.89M-$34.96M-$31.22M-$16.17M
Capital expenditures$14.30K$16.34K$130.40K$87.98K
Investing cash flow-$14.30K-$14.07K-$130.40K-$85.79K
Financing cash flow$4.49M-$5.14M$81.98M$43.05M
Net change in cash-$36.40M-$40.16M$50.62M$26.80M
Stock-based compensation$1.34M$2.55M$4.67M$2.38M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$67.13K$77.46K$86.07K$34.52K

Derived

Hepion Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-31
Free cash flow-$40.90M-$34.98M-$31.35M-$16.25M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio3.31x7.16x11.88x9.15x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HEPA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-19View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.